Results 91 to 100 of about 144,727 (384)

An in vivo systemic massively parallel platform for deciphering animal tissue-specific regulatory function

open access: yesFrontiers in Genetics
Introduction: Transcriptional regulation is an important process wherein non-protein coding enhancer sequences play a key role in determining cell type identity and phenotypic diversity.
Ashley R. Brown   +27 more
doaj   +1 more source

Cortical AAV-CNTF gene therapy combined with intraspinal mesenchymal precursor cell transplantation promotes functional and morphological outcomes after spinal cord injury in adult rats [PDF]

open access: yes, 2018
Ciliary neurotrophic factor (CNTF) promotes survival and enhances long-distance regeneration of injured axons in parts of the adult CNS. Here we tested whether CNTF gene therapy targeting corticospinal neurons (CSN) in motor-related regions of the ...
Akinpelu, Emmanuel A   +14 more
core   +3 more sources

Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids

open access: yesbioRxiv, 2019
The engineered AAV-PHP.B family of adeno-associated virus efficiently delivers genes throughout the mouse central nervous system. To guide their application across disease models, and to inspire the development of translational gene therapy vectors ...
Qin Huang   +10 more
semanticscholar   +1 more source

Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme

open access: yesJCI Insight, 2020
Preexisting humoral immunity to recombinant adeno-associated virus (AAV) vectors restricts the treatable patient population and efficacy of human gene therapies.
Zachary C. Elmore   +4 more
semanticscholar   +1 more source

Lecithin Alleviates Memory Deficits and Muscle Attenuation in Chinese Older Adults and SAMP8 Mice

open access: yesAdvanced Science, EarlyView.
This study opens a new avenue for safeguarding cognition and muscle health, averting disability in older age, and treating age‐related pathologies through lecithin supplementation. It serves as a promising nonpharmacological intervention for the crosstalk of muscle and cognition.
Xianyun Wang   +16 more
wiley   +1 more source

Targeting tauopathy with engineered tau-degrading intrabodies [PDF]

open access: yes, 2019
BACKGROUND: The accumulation of pathological tau is the main component of neurofibrillary tangles and other tau aggregates in several neurodegenerative diseases, referred to as tauopathies.
Gallardo, Gilbert   +7 more
core   +1 more source

AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes

open access: yesMolecular Therapy - Methods & Clinical Development, 2015
Adeno-associated virus (AAV) has become one of the most promising vectors in gene transfer in the last 10 years with successful translation to clinical trials in humans and even market approval for a first gene therapy product in Europe. Administration to humans, however, revealed that adaptive immune responses against the vector capsid can present an ...
Daniel J Hui   +9 more
openaire   +4 more sources

Self‐Adjusting Engineered Probiotic for Targeted Tumor Colonization and Local Therapeutics Delivery

open access: yesAdvanced Science, EarlyView.
Zou et al. developed an engineered strain of Escherichia coli Nissle 1917 with precise targeting abilities for colonization and on‐demand payload release. The engineered probiotic survives and embolizes tumors only in the presence of more than 5 mM L‐lactate. Furthermore, the introduction of an α‐hemolysin circuit enhances its anti‐tumor effect.
Zhen‐Ping Zou   +8 more
wiley   +1 more source

Long-term Evaluation of AAV-CRISPR Genome Editing for Duchenne Muscular Dystrophy

open access: yesNature Network Boston, 2018
Duchenne muscular dystrophy (DMD) is a monogenic disorder and a candidate for therapeutic genome editing. There have been several recent reports of genome editing in preclinical models of Duchenne muscular dystrophy1–6, however, the long-term persistence
Christopher E. Nelson   +11 more
semanticscholar   +1 more source

Exploring AAV‐Mediated Gene Therapy for Inner Ear Diseases: from Preclinical Success to Clinical Potential

open access: yesAdvanced Science, EarlyView.
Current preclinical studies of AAV‐mediated gene therapy explore different strategies based on the characteristics of inner ear diseases. For genetic hearing loss, approaches include the replacement of a “good gene,” removal of a “bad gene,” or direct correction of mutations through base editing.
Fan Wu   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy